Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran

Table 3

Association between gene expression and antimicrobial nonsusceptibility in ESBL-producing E. coli.

Antimicrobial agents	TEM		CTX		VEB		SHV
	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative
Cephalosporins
Cefepime	38 (77.6%)	42 (82.4%)	23 (82.1%)	57 (79.2%)	6 (75%)	74 (80.4%)	38 (86.4%)	42 (75%)
Cefixime	49 (100%)	50 (98%)	27 (96.4%)	72 (100%)	8 (100%)	91 (98.9%)	43 (97.7%)	56 (100%)
Ceftriaxone	29 (59.2%)	41 (80.4%	22 (78.6%)	48 (66.7%)	4 (50%)	66 (71.7%)	33 (75%)	37 (66.7%)
Ceftazidime	22 (44.9%)	23 (45.1%)	11 (39.3%)	34 (47.2%)	6 (75%	39 (42.4%)	17 (38.6%)	28 (50%)
Ceftizoxime	34 (69.4%)	39 (76.5%)	23 (82.1%)	50 (69.4%)	6 (75%)	67 (72.8%)	32 (12.7%)	41 (73.2%)
Cefotaxime	21 (42.9%)	32 (62.7%	18 (64.3%)	35 (48.6%)	5 (62.5%)	48 (52.2%)	21 (47.7%)	32 (57.1%)
Carbapenems
Imipenem	14 (28.6%)	20 (39.2%)	11 (39.3%)	23 (31.9%)	3 (37.5%)	31 (33.7%)	15 (34.1%)	19 (34%)
Meropenem	12 (24.5%)	21 (42.2%)	9 (32.1%)	24 (33.3%)	3 (37.5%)	30 (32.6%)	13 (29.5%)	20 (35.7%)
Aminoglycosides
Amikacin	14 (28.6%)	28 (54.9%	13 (46.4%)	29 (40.3%)	3 (37.5%)	39 (42.4%)	24 (54.5%	18 (32%)
Gentamicin	21 (42.9%)	28 (54.9%)	14 (50%)	35 (48.6%)	5 (62.5%)	44 (47.8%)	27 (61.4%	22 (39.3%)
Others
Ciprofloxacin	34 (69.4%)	42 (82.4%)	21 (75%)	55 (76.4%)	5 (62.5%)	71 (77.2%)	39 (88.6%	37 (66%)
Colistin	39 (79.6)	43 (84.3%)	23 (82.1%)	59 (81.9%)	6 (75%)	76 (82.6%)	38 (86.4%)	44 (78.6%)
TMP/SXT	34 (69.4%)	38 (74.5%)	21 (75%)	51 (70.8%)	4 (50%)	68 (73.9%)	29 (65.9%)	43 (76.8%)
Pip/TBZ	29 (59.2%)	29 (59.2%)	15 (53.6%)	43 (59.7%)	4 (50%)	4 (50%)	25 (56.8% )	33 (59%)

: resistance, : intermediate, : sensitive, and ESBL: extended-spectrum beta-lactamase.
Significant differences ( < 0.05).